Skip to main content
. 2020 Apr 24;9(9):e014347. doi: 10.1161/JAHA.119.014347

Figure 3. Factors associated with the risk of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy interruption.

Figure 3

In this figure, older age and residence in the South and West census regions of the United States vs the Northeast census region were associated with higher likelihood of PCSK9i interruption, whereas patients on ezetimibe at the time of PCSK9i initiation were associated with lower likelihood of PCSK9i interruption. CAD indicates coronary artery disease; CVD, cardiovascular disease; PAD, peripheral artery disease; and TIA, transient ischemic attack.